Literature DB >> 15724807

The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder--clinical procedures and research perspectives.

U Halbreich1.   

Abstract

Premenstrual syndromes (PMS) are quite prevalent among women of reproductive age. In up to 20% of women they are severe enough to warrant treatment, which is available and marketed as such. The impact of the cumulative burden of PMS is substantial and is in the same magnitude as affective disorders. Nevertheless, the definitions and diagnoses of PMS are still fragmented, not widely accepted and, if accepted, not always applied in day-to-day clinical practice. In the present paper, the current diagnostic entities are critically reviewed, problems with the current definitions are delineated and a unified definition is proposed. For clinical purposes, the recommended dinical practical diagnostic process and differential diagnosis are described. For clinical trials of medications for treatment of PMS/premenstrual dysphoric disorder, research diagnostic criteria, inclusion and exclusion criteria, as well as well-defined outcome measures, are of utmost importance; they are described here. The gaps of knowledge in the description and diagnosis of PMS are described, with suggestions for future directions for research.

Entities:  

Mesh:

Year:  2004        PMID: 15724807     DOI: 10.1080/0951590400018215

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  23 in total

1.  Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three-arm randomized controlled trial.

Authors:  Tory A Eisenlohr-Moul; Susan S Girdler; Jacqueline L Johnson; Peter J Schmidt; David R Rubinow
Journal:  Depress Anxiety       Date:  2017-07-17       Impact factor: 6.505

2.  Pilot study of the efficacy and safety of a modified-release magnesium 250 mg tablet (Sincromag) for the treatment of premenstrual syndrome.

Authors:  S Quaranta; M A Buscaglia; M G Meroni; E Colombo; S Cella
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

3.  Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels.

Authors:  Peter J Schmidt; Pedro E Martinez; Lynnette K Nieman; Deloris E Koziol; Karla D Thompson; Linda Schenkel; Paul G Wakim; David R Rubinow
Journal:  Am J Psychiatry       Date:  2017-04-21       Impact factor: 18.112

4.  Ecological validity and clinical utility of Patient-Reported Outcomes Measurement Information System (PROMIS®) instruments for detecting premenstrual symptoms of depression, anger, and fatigue.

Authors:  Doerte U Junghaenel; Stefan Schneider; Arthur A Stone; Christopher Christodoulou; Joan E Broderick
Journal:  J Psychosom Res       Date:  2014-02-07       Impact factor: 3.006

Review 5.  Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?

Authors:  Uriel Halbreich; P M Shaughn O'Brien; Elias Eriksson; Torbjörn Bäckström; Kimberly A Yonkers; Ellen W Freeman
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 6.  Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus.

Authors:  Patrick Michael Shaughn O'Brien; Torbjorn Bäckström; Candace Brown; Lorraine Dennerstein; Jean Endicott; C Neill Epperson; Elias Eriksson; Ellen Freeman; Uriel Halbreich; Khaled M K Ismail; Nicholas Panay; Teri Pearlstein; Andrea Rapkin; Robert Reid; Peter Schmidt; Meir Steiner; John Studd; Kimberley Yonkers
Journal:  Arch Womens Ment Health       Date:  2011-01-12       Impact factor: 3.633

7.  Predicting response to leuprolide of women with premenstrual dysphoric disorder by daily mood rating dynamics.

Authors:  Steven M Pincus; Shaista Alam; David R Rubinow; Chaya G Bhuvaneswar; Peter J Schmidt
Journal:  J Psychiatr Res       Date:  2010-08-13       Impact factor: 4.791

8.  Luteal serum BDNF and HSP70 levels in women with premenstrual dysphoric disorder.

Authors:  E Oral; H Ozcan; T S Kirkan; S Askin; M Gulec; N Aydin
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-03-02       Impact factor: 5.270

9.  Intake of selected minerals and risk of premenstrual syndrome.

Authors:  Patricia O Chocano-Bedoya; Joann E Manson; Susan E Hankinson; Susan R Johnson; Lisa Chasan-Taber; Alayne G Ronnenberg; Carol Bigelow; Elizabeth R Bertone-Johnson
Journal:  Am J Epidemiol       Date:  2013-02-26       Impact factor: 4.897

10.  Effects of aerobic exercise at different intensities in pre menstrual syndrome.

Authors:  R Vishnupriya; P Rajarajeswaram
Journal:  J Obstet Gynaecol India       Date:  2012-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.